Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acro Biomedical CoROCO:6748 -2.78%68 Quick Ratio is 61.23 as of Jun. 2026, which is 129% above its 10-year median of 26.69. GuruFocus rates ROCO:6748 with a GF Score™ of 68/100 and a GF Value™ of NT$47.04 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Acro Biomedical Co ranks better than 99.22% on this metric.
Acro Biomedical Co (ROCO:6748) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Acro Biomedical Co Quick Ratio Related Terms
Acro Biomedical Co Quick Ratio Historical Data
* Premium members only.
The historical data trend for Acro Biomedical Co's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6748 vs VRTX, REGN, MRNA: Quick Ratio Comparison
For the Biotechnology subindustry, Acro Biomedical Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acro Biomedical Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acro Biomedical Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Acro Biomedical Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Acro Biomedical Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acro Biomedical Co (ROCO:6748) has a Quick Ratio of 61.23 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Acro Biomedical Co and its competitors. This is 129% above median its historical median of 26.69. Over the past decade, Acro Biomedical Co's Quick Ratio has ranged from 7.24 to 61.23. According to the industry distribution chart, Acro Biomedical Co ranks #11 out of 1410 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Acro Biomedical Co's Quick Ratio too high?
Acro Biomedical Co's current Quick Ratio of 61.23 is 129% above median its 10-year median of 26.69. Over the past 10 years, this metric has ranged from a low of 7.24 to a high of 61.23. The Biotechnology industry median Quick Ratio is 3.68. Acro Biomedical Co's value of 61.23 is 1566.1% above this industry median. Based on the distribution chart, Acro Biomedical Co ranks #11 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Acro Biomedical Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acro Biomedical Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acro Biomedical Co ranks #11 out of 1410 companies for Quick Ratio. This places Acro Biomedical Co in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.68. Acro Biomedical Co's value of 61.23 is 1566.1% above this benchmark. Historically, Acro Biomedical Co's own Quick Ratio has ranged from 7.24 to 61.23 over the past decade. While the company's 10-year median is 26.69 vs. the industry median of 3.68, Acro Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.68, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acro Biomedical Co's current Quick Ratio of 61.23 is 1566.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Acro Biomedical Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acro Biomedical Co's current Quick Ratio is 61.23, which is 129% above median its own 10-year median of 26.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Acro Biomedical Co (ROCO:6748) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$47.04, compared to a current price of NT$175.00 — trading 272% above its estimated fair value. The current Quick Ratio is 61.23, which is 129% above median its 10-year median of 26.69 and 1566.1% above the Biotechnology industry median of 3.68. Acro Biomedical Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Acro Biomedical Co (ROCO:6748), the current Quick Ratio is 61.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acro Biomedical Co (ROCO:6748) Overvalued in 2026?
Based on GuruFocus' analysis, Acro Biomedical Co stock appears to be overvalued.
The current stock price of NT$175.00 is trading 272% above its estimated GF Value™ of NT$47.04.
GuruFocus considers Acro Biomedical Co to be Significantly Overvalued.
Key valuation signals for ROCO:6748:
Quick Ratio: 61.23 (129% above median its 10-year median of 26.69)
GF Value™: NT$47.04 vs. price of NT$175.00 (272% above fair value)
Industry Position: 1566.1% above the Biotechnology median (#11 of 1410)
No single metric tells the full story. See the ROCO:6748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acro Biomedical Co Ltd is a company whose technical team integrates the Research and development capabilities of Taiwan's major scientific research units and medical centers to jointly develop equipment for repairing organs and tissues in various parts of the human body. It mainly focuses on orthopedics, dentistry, cardiovascular specialists, ophthalmology, surgery, wound care, Medical equipment used in sports injuries and other specialties.
68GF Score
Get the complete analysis for ROCO:6748
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6748 has been successfully added to your 
